Brief: Shilpa Medicare Says Shilpa Pharma Lifesciences Unit-1 Receives EIR From USFDA
14/05/2025 16:27
May 14 (Reuters) - Shilpa Medicare Ltd SHME.NS: SHILPA PHARMA LIFESCIENCES UNIT-1 RECEIVES EIR FROM USFDA SITE CLASSIFIED AS VAI BY USFDA Source text: ID:nBSE5ZkBKd Further company coverage: SHME.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026